Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have evaluated its safety and efficacy in patients with coronavirus disease 2019 (COVID-19), and these studies demonstrate conflicti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ohoud Aljuhani, Khalid Al Sulaiman, Adel Alshabasy, Khalid Eljaaly, Abdulrahman I. Al Shaya, Haytham Noureldeen, Mohammed Aboudeif, Bodoor Al Dosari, Amina Alkhalaf, Ghazwa B. Korayem, Muneera M. Aleissa, Hisham A. Badreldin, Shmeylan Al Harbi, Abdullah Alhammad, Ramesh Vishwakarma
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	COVID-19 SARS-Cov-2 Tocilizumab Secondary infection CRE Critically ill Infectious and parasitic diseases RC109-216
Acceso en línea:	https://doaj.org/article/c8d00252251f49ceb5ec2537a6f9c97e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Ejemplares similares